LNA-043 is under clinical development by Novartis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect LNA-043’s likelihood of approval (LoA) and phase transition for Osteoarthritis took place on 07 Oct 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LNA-043 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
LNA-043 is under development for the treatment of osteoarthritis. It is administered intra-articularly. The drug candidate acts by targeting angiopoietin related protein 3 (ANGPTL3). It is a new molecular entity (NME).
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Quick View LNA-043 LOA Data
|Highest Development Stage|